OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
OS Therapies tested a new bone cancer medicine and found it helped patients live longer than the old treatment—71% versus 46% after three years. When a company shows their medicine works better, people often get more interested in that company, so it's worth watching how investors react.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.